the hypothesis that EDLFs are endogenous compounds other than the steroids and lipids also investigated.
INDEXING mIuiS:
sample preparation #{149} sodium pump #{149} ligand binding #{149} acetonitrile The Na/Kt.ATPase or sodium pump is the plasma membrane enzyme that catalyzes the active transport of sodium and potassium across the cell membrane, playing a fundamental role in many cellular functions (for review see [1J) . A unique feature of the Na/K-ATPase is the sensitivity to inhibition by a class of glycosylated steroids that function through binding to a specific site that has been highly conserved during evolution [2] . This cardiac glycoside binding site has long been postulated to be the target of some natural ligand(s) [endogenous digitalis-like factor(s) (EDLF)I (for review see 3)I However, despite the large number of studies, the origin and molecular nature of EDLF have not yet been unequivocally defined (for review see 3 and 4), and some workers have even doubted its existence [5] .
One of the difficulties in the progress of EDLF research has been the lack of a unique, specific screening assay for EDLF [3, 6] . On the assumption that an endogenous digitalis-like material must reproduce the major biological actions of the cardiac glycosides, inhibition of Na /K-ATPase activity, inhibition of sodium or potassium transport in intact cells, and inhibition of H-ouabain binding to receptors have been used. Many researchers have also used RIA for digoxin [7, 8] , but the possible physiological role of digoxin-like immunoreactivity has been a matter of much controversy [9] . Previously, Hamlyn et al., in view of their results on EDLF identification in human plasma [10] , have proposed an immunoassay specific for ouabain to detect EDLF [11] . Immunoreactive ouabain has been reported in clinical and experimental disorders [12] , but recent papers [13, 14] have issued some criticism to these findings.
Our approach was based on the premise that competition for cardiac glycoside binding sites was an absolute requirement for EDLF, and on the belief that the radioreceptor assay (RRA) presents major advantages compared with immunoassays in detecting unknown substances that cross-react with receptors to exert their activity, though having the same ease of application. RRA, moreover, is in general more accurate and much simpler to carry out than many of the conventional bioassay techniques. Also, the receptor radioligand system is more sensitive to the action of the cardiac glycosides than the enzyme assay procedure, even though differences in sensitivity are influenced by the assay conditions or the species from which Na/K-ATPase is derived [3] . In previous papers [15, 16] we reported that human placenta is a rich tissue source for cardiac glycoside binding sites, and proposed competitive binding to placental digitalis receptors as a useful tool to detect EDLF in biological fluids. In that assay, however, we encountered problems of poor sensitivity and precision. 
SPECIMENS

Heparinized
blood and overnight urine samples were obtained from apparently healthy men and women not taking digoxin and belonging to our laboratory staff (ages 20-55 years). Urine specimens were also obtained from healthy newborns (lst-5th day of extrauterine life). Cord blood was collected from the placental vein immediately after normal delivery from women with uncomplicated pregnancy and was transferred into heparinized tubes. Plasma was recovered within 1 h by centrifugation at 4 #{176}C. All plasma and urine samples without preservatives were stored at -20 #{176}C in different aliquots until extracted.
Pools for quality control, linearity test, and extraction experiments were prepared with cord blood plasma (CBP), urine samples from newborns, and plasma and urine samples from healthy adults. Pools were divided into aliquots and stored at -20 #{176}C until use. Two plasma pools from >20 pregnant women in the second and third trimester of pregnancy were also used.
Patients' samples used in this study were collected in accordance with the ethical requirements of our institution. the Sep-Pak cartridge was mounted on a syringe. All solutions and samples were passed slowly (lg) through the resin, and the sorbent was not allowed to dry out.
PROCEDURES
Two-step solid-state extraction of human placma with acetonitrile.
Two milliliters of plasma was passed through C,8 cartridges preconditioned with 4 mL of acetonitrile, followed by 20 mL of 1 mL/L trifluoroacetic acid (TFA). Unbound materials were washed off the resin with 10 mL of I mL/L TFA. Then, more polar materials were eluted with 3 mL of 250 mL/L acetonitrile in 1 mL/L TFA and, subsequently, the less polar compounds with 3 mL of acetonitrile.
Both eluates were collected, evaporated to dryness, and stored at -20 #{176}C until assayed.
Before RRA, all dried residues were reconstituted in RRA-HSA buffer (usually 0.12 mL), thoroughly vortex-mixed, sonicated for 5 mm, and centrifuged at 2000g for 10 mm at 4 #{176}C.
EXTRACTION RECOVERY STUDIES
Twenty microliters of
or 5 ML of '251-labeled digoxin plus unlabeled digoxin (1 nmoVL, final concentration) was added to 20 mL of CBP or urine samples. After incubation at 37 #{176}C for 30-60 mm, two l-mL aliquots were removed for counting of total radioactivity, and 2-mL (or 3-5-mL) aliquots were extracted according to the procedures previously described. All the rinses and the eluates were collected and counted. The amounts recovered at each step were expressed as a percent of the radioactivity present in the sample volume applied.
ANALYTICAL VARIABLES
Linearity. Control pools were extracted according to the procedures outlined above. Dried residues were reconstituted with a small volume of RRA-HSA buffer, mixed, and assayed at various dilutions.
Precision. The within-run precision was estimated by extracting the same control pool with different cartridges and determining EDLF by RRA either on each extract (combined precision of both column-to-column and EDLF analysis) or after mixing the extracts from different cartridges.
The between-run reproducibility was determined over 2-8 months by assaying one or two daily reconstituted extracts of control pools. In some cases, we assessed our assay for precision by replicate or triplicate analysis of various human plasmas and urines.
CROSS-REACTIVITY STUDIES
All steroids and digoxin metabolites were dissolved initially in pyridine at 10 mmol/L.
Cortisol was dissolved in dioxane (50 mmol/L). Lysophosphatidyl choline and oleic acid were made up to a stock concentration of 10 mmol/L and I mol/L, respectively, in ethanol. Each stock solution was then diluted in RRA-HSA buffer to give the final concentrations reported in Fig. 4 . Equivalent dilutions of pyridine, dioxane, and ethanol with buffer were carried out for control experiments. Arachidonic acid (sodium salt) was directly diluted in RRA-HSA buffer.
DATA ANALYSIS
Data are usually expressed as the mean ± SD. The interpolation of the dose-response curve, the precision profile, and all values for samples were calculated by previously described computer programs [17, 18] 
Results
In preliminary experiments we observed that '251-labeled digoxin was "sticky" and bound to test tubes and filters. We found that nonspecific absorption of digoxin could be minimized by the use of glassware and the inclusion of 1 g/L HSA in the assay buffer. SENSITIVITY We also observed that the use of high-speed centrifugation to separate bound from free ligand [15, 16] led to the loss of >20% of the receptor proteins in the supernates, produced a high nonspecific binding (20.5 ± 2.8% of the total bound), and resulted in an artifactual underestimation of the sensitivity of the RRA. As shown in Fig. 1 for plasma specimens.
Here, the concentrations of potential interfering substances such as progesterone, cortisol, and free fatty acids were lower than in all other extracts (not shown). An 
DILUTION LINEARITY
The mean concentrations of digoxin-like and ouabain-like activity as measured by RRA in different extracts of pooled CBP at several dilutions are plotted in Fig. 3 as a function As concerns extracts of pooled urine samples, linear curves passing through the origin were found for data expressed either as digoxin or ouabain equivalents (not shown). A "dilution effect" was observed, however, when the sample volume assayed was >1.5 mL/tube. plasma and urine extracts. \Vhen the precision was estimated by the method of duplicates, a precision profile similar to that reported in the inset of Fig. 2 was obtained. 
EXTRACTION RECOVERY STUDIES
INTERFERENCES
Analysis of the apparent cross-reactivities of various compounds (Fig. 4) showed that none of the steroids tested had an appreciable cross-reactivity up to 10 .tmol/L. [3] . Oleic acid did not displace the tracer even at I mmol/L (Fig. 4, lower left) . Higher concentrations of all substances would have involved the use of an unacceptable amount of organic solvent in the RRA. Interestingly, in the presence of oleic acid the percentage of '251-labeled digoxin binding was much higher than 100% for all the concentrations studied. As expected, potassium was a potent inhibitor of the binding, with an IC() of 1.38 ± 0.09 mmol/L (Fig. 4,  lower right) . The metabolites of digoxin cross-reacted in the RRA in proportion to their respective cardioactivity. At 30 nmol/L, 58% and 68% of the radioactivity bound to placental particulates was displaced by digitoxigenin and digoxigenin, respectively, whereas the same concentration of digitoxose, a cardioinactive digoxin metabolite, had no or little effect on tracer binding (Fig. 4, lower right) .
EDLF CONCENTRATIONS IN SUBJECT GROUPS
Plasma EDLF concentrations in healthy adults, newborns, and pregnant women are given in Table 2 
Discussion
Competition for the digitalis receptor on the Na/K-ATPase is "conditio sine qua non" for EDLF. The receptor radioligand system, therefore, appears to be a suitable method for the detection of EDLF in clinical studies and an appropriate means to discriminate EDLF from other NaJK-ATPase inhibitors. Since pure EDLF in quantities adequate for use in the calibration curve and as a tracer is not available, a "true" RRA for EDLF cannot be developed. The RRA proposed here to detect EDLF in human plasma and urine is based on the competitive replacement of '251-labeled digoxin on the human placenta digitalis receptors by ligands present in sample extracts. EDLF values were expressed as digoxin-and ouabain-equivalent concentrations by referring tracer binding inhibition by the extracts to digoxin and ouabain calibration curves, respectively.
A major goal in developing any RRA is to optimize the sensitivity and precision of the assay. Optimum conditions were here established for each step of the procedure. Nonspecific absorption of '251-labeled digoxin was minimized by the use of glassware and the inclusion of 1 g/L HSA in the assay buffer. The presence of albumin did have a 25-30% nonspecific inhibitory effect on tracer binding to receptors, presumably because HSA binds the radioactive ligand and makes it unavailable to receptors. However, the comparison of normalized calibration curves run with or without HSA showed no significant difference in the detection limit of the assay. Separation of bound from free ligand was accomplished by filtration through glass fiber filters. This procedure is different from that previously reported from this laboratory [15, 16] [19] [20] [21] [22] [23] . Although we have at present no definitive data on the Na/K-ATPase isoforms of the human placenta or on the stability of different isoforms with storage, we found that human placenta exhibited several advantages over other tissues. Under our RRA conditions, in fact, the affinity for digoxin of placental Na/K-ATPase, as expressed by the IC50, was similar to that shown by the enzyme isolated from human heart at autopsy [20] and higher than that for dog kidney Na/K-ATPase [20] . The IC5() for ouabain, moreover, was comparable with the reported
K1) value of [3H]ouabain
binding to intact human erythrocytes [22] and considerably lower than that for rat brain synaptosomes [21, 22] . Unlike the human heart, however, the human placenta is easily available, can be processed immediately after delivery, and yields large amounts of microsomal membranes, -4 mg of protein per gram of fresh tissue, compared with 0.16 mg of protein per grain of human heart at autopsy [20] . In addition, placental membranes can be stored up to 10 months at -70 #{176}C without loss of digitalis drug-binding activity. The same lot of membranes can be therefore used for many experiments. Human heart membranes, by contrast, were reported to be used for as long as 2 weeks [20] , and human erythrocytes require daily (or every few days) isolation from the same donor. An apparent three-to fourfold individual variation of the apparent IC50 for inhibition of the human erythrocyte sodium pump by ouabain has been, in fact, previously reported [24] . As compared with Na/K-ATPase from animal tissues, the higher affinity of the human placenta digitalis receptor for the tracer and the variability of subunit isoforms among species [1, 2] favor our initial hypothesis that EDLF detection in humans could be better achieved by human rather than animal Na /K -ATPase. and the other one with a polarity more similar to that of digoxin (EDLF-2, eluted subsequently with acetonitrile), were separated from human plasma. Only one fraction of low polarity was obtained from human urine by one-step solid-state extraction with methanol.
We do not know at present why no EDLF activity could be recovered from plasma specimens with methanol, since this procedure allowed the complete recovery of either ouabain or digoxin added to plasma. Some unidentified interfering substances or "matrix effects" that mask EDLF inhibition of radioligand binding to receptors are possibly eluted from the resin. However, 250 mL/L acetonitrile elution of plasma samples greatly improved the purity of the final extract, minimizing the presence of compounds that may interfere with the assay. Reproducibility of our RRA was acceptable, with within-run CVs 5-10% and between-run CVs comparable with the values found in RRAs of other substances.
Similar CVs were obtained with plasma and urine extracts, indicating the absence of a matrix effect. A lower interassay CV has been reported in the human heart RRA for digoxin [20] , whereas within-run CVs of 21% and 10% were reported for the same RRA with dog kidney membranes [19] . Both methods, however, were developed for the therapeutic drug monitoring of digoxin in the nanomolar range. No data, by contrast, have been reported on the reproducibility of the RRAs used to monitor EDLF purification from biological tissues [21] [22] [23] [24] . In agreement with other studies [4, 8, 29] , plasma EDLF in newborns and pregnant women was higher than in healthy adults, and the concentrations in urine were higher than in plasma. Interestingly, women in the second and third trimester of pregnancy had increased plasma concentrations of EDLF-2, whereas EDLF-i was nearly undetectable, suggesting that the factors present in pregnancy differ from those present in the other two subject groups.
We cannot currently eliminate the possibility that EDLF-2 may represent a nonspecific interference due to endogenous steroids or lipids suggested as EDLF in mammalian plasma [21, 30-3 3] . Our cross-reactivity experiments, however, indicate that only supraphysiological concentrations of the substances tested, and higher than those remaining after C18 solid-state extraction, were able to inhibit binding, if any. Progesterone, a slightly cardioactive steroid [34] , cross-reacted minimally at 10 mmol/L, as already previously reported in other tissues [20] , but could not account for values measured in our extracts.
We cannot also eliminate the possibility that EDLF-l and EDLF-2 may represent the same material(s) in part. However, the lack of correlation between EDLF-l and EDLF-2 (expressed both as ouabain-and digoxin-equivalent concentrations) and the correlation between data expressed in ouabainand digoxin-equivalent concentrations for either EDLF-l or EDLF-2 strongly support the hypothesis that two distinct EDLFs, which parallel ouabain and digoxin in the interaction with placental receptors, exist in human plasma. One should note, in this respect, that the heterogeneity of Na /K' -ATPase inhibitor in human plasma has been previously documented [35] [36] [37] .
In conclusion, the RRA developed proved to be simple, highly specific, and sensitive. It afforded good precision and used stable reagents. EDLF could be purified and concentrated from biological fluids by disposable C18 cartridges.
In the RRA, as used routinely in our laboratory, 20-40 biological samples can be carried through the extraction procedure in an afternoon.
In the binding assay, 80-100 samples can be readily processed in 1 day. Thus, the RRA permits the measurement of EDLF in 50 or more samples daily. The results can be expressed equally well as digoxin-and ouabain-equivalent concentrations. The results of the present study confirm that endogenous ligands of digitalis receptors do exist in human body fluids and suggest that two distinct EDLF activities may be separated from human plasma. Only one fraction seems to be present in human urine.
The fact that physiological concentrations of endogenous steroids and lipids were not able to inhibit '251-labeled digoxin binding to placental digitalis receptors supports the hypothesis that EDLFs are endogenous compounds other than the steroids and lipids investigated.
Whether different EDLF species exist in different physiopathological conditions remains unclear.
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